<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01876615</url>
  </required_header>
  <id_info>
    <org_study_id>YH4808-109</org_study_id>
    <nct_id>NCT01876615</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Drug Interaction Between YH4808 and Diclofenac</brief_title>
  <official_title>A Randomized, Open-Label, Single-dosing and Cross-over Clinical Trial to Investigate the Safety and Pharmacokinetic Drug-Drug Interaction of YH4808 and Diclofenac in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare pharmacokinetics after single oral administration
      of YH4808 and Diclofenac each separately versus coadministration of YH4808 and Diclofenac in
      healthy male volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of YH4808</measure>
    <time_frame>18 points up to Day 2 or Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of YH4808</measure>
    <time_frame>18 points up to Day 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of YH4808</measure>
    <time_frame>18 points up to Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Diclofenac</measure>
    <time_frame>16points up to Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of YH4808</measure>
    <time_frame>18 points up to Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Diclofenac</measure>
    <time_frame>16 points up to Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of YH4808</measure>
    <time_frame>18 points up to Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Diclofenac</measure>
    <time_frame>16 points up to Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic ratio</measure>
    <time_frame>18 points up to Day 3</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac(arm 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 arm, 3 Sequence design
YH4808 or Diclofenac or YH4808+Diclofenac
3 week wash out period is between each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac (arm 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 arm, 3 Sequence design
YH4808 or Diclofenac or YH4808+Diclofenac
3 week wash out period is between each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac (arm 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 arm, 3 Sequence design
YH4808 or Diclofenac or YH4808+Diclofenac
3 week wash out period is between each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac (arm 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 arm, 3 Sequence design
YH4808 or Diclofenac or YH4808+Diclofenac
3 week wash out period is between each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac (arm5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 arm, 3 Sequence design
YH4808 or Diclofenac or YH4808+Diclofenac
3 week wash out period is between each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac (arm6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 arm, 3 Sequence design
YH4808 or Diclofenac or YH4808+Diclofenac
3 week wash out period is between each period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH4808</intervention_name>
    <description>experimental drug</description>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac(arm 1)</arm_group_label>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac (arm 2)</arm_group_label>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac (arm 3)</arm_group_label>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac (arm 4)</arm_group_label>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac (arm5)</arm_group_label>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac (arm6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
    <description>Depain tablet 25mg</description>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac(arm 1)</arm_group_label>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac (arm 2)</arm_group_label>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac (arm 3)</arm_group_label>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac (arm 4)</arm_group_label>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac (arm5)</arm_group_label>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac (arm6)</arm_group_label>
    <other_name>Depain tablet 25mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH4808+Diclofenac</intervention_name>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac(arm 1)</arm_group_label>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac (arm 2)</arm_group_label>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac (arm 3)</arm_group_label>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac (arm 4)</arm_group_label>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac (arm5)</arm_group_label>
    <arm_group_label>YH4808 or Diclofenac or YH4808+Diclofenac (arm6)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male age 20 to 45 over 55kg with Ideal body weight(IBW)

          -  No clinically important abnormal physical findings at the screening examination

          -  Subject who has no congential, chronic disease and disease symptoms in medical
             examination result

          -  Subject who is judged to be eligible by principal inverstigator or sub-investigator
             according to various reasons includiong ther abnorminal test results(clinical
             laboratory test, 12-lead GCG etc)

          -  Ability to communicate well with the inverstigator and to comply with the requremetns
             of the entire study

          -  Willingness to give written informed consent(prior to any study-related procedures
             beinging performed) and to be able to adhere to the study restrictions and examination
             schedule

        Exclusion Criteria:

          -  Suject who has history or presence of clinically significant diseases in liver,
             kidney, gastrointestinal tract, nervous system, respiratory system, endocrine system,
             blood tumor, cardiovascular, urinary system, and mental disorder

          -  Subject who is hypersensitive to components contained in YH4808 or declofenac or
             related drug(ex. rebamipide, revaprazan, NSID etc)

          -  Medical history of gastrointestinal disease or acid restraining surgery, gastric/
             esophagus surgery(excluding appendectomy, hernia surgery)

          -  Subject who has history of drug dependence or using that drug

          -  Subject who had taken usual dose of any prescription durgs within 14 days before the
             treatment or who had used usual dose of OTC drugs within 7 days before the treatment

          -  Subject who participated in antoher clinical trial within 2 monthes before enrolling
             in this study

          -  subject who donated whole blood within 2 months or component blood within 1 month
             before the treatment

          -  Subject who drank over 21unit/week(1 unit= 10g of alcohol) or were not able to refrain
             from drinking alcohol during study days

          -  Subject who stopped smoking within 3 months before the treatment or detected cotinine
             in urine test

          -  Subject with clinically significant observations considered as unsuitable based on
             medical judgment by the investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janghee Hong, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2013</study_first_submitted>
  <study_first_submitted_qc>June 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2013</study_first_posted>
  <last_update_submitted>December 31, 2013</last_update_submitted>
  <last_update_submitted_qc>December 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety/tolerability and pharmacokinetics/pharmacodynamics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

